Aleta Biotherapeutics’ CTEs address this challenge by enhancing the expression of CAR T

Aleta Biotherapeutics’ CTEs address this challenge by enhancing the expression of CAR T target antigens on tumor cells, making them more recognizable and vulnerable to CAR T cells. These CTEs are designed as simple,biologic agents that can be administered to patients, working synergistically with existing CAR T therapies to boost their potency and broaden their applicability across a wider range of cancers. By enabling CAR T therapies to target multiple antigens simultaneously, Aleta’s CTEs hold the potential to overcome some of the key limitations of current CAR T treatments. This multiantigen targeting approach is particularly promising for treating solid tumors, which have historically been more challenging for CAR T therapies to address due to their complex and heterogeneous nature.